Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity

Anti-Cancer Drugs

Volumn 18, Issue 7, 2007, Pages 809-816

  Singh, Ravibhushan ^a   Browning, Jeff L ^a   Abi Habib, Ralph ^a   Wong, Kevin ^c   Williams, Simon A ^b   Merchant, Rosemina ^c   Denmeade, Samuel R ^b   Buckley, Thomas J ^d   Frankel, Arthur E ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Protox Therapeutics Inc   (Canada)

^d UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Proaerolysin; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; ANDROSTANOLONE; FURIN; PROAEROLYSIN; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; PROTOXIN; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

AEROMONAS SALMONICIDA; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER;

AEROMONAS SALMONICIDA; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENETIC ENGINEERING; HUMANS; MALE; PEPTIDE HYDROLASES; PORE FORMING CYTOTOXIC PROTEINS; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 34250846978     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280bad82d     Document Type: Article

References (32)

1. Naslund MJ, Issa M, Grogg AL, Eaddy MT, Black L. Clinical and economic outcomes in patients treated for enlarged prostate. Am J Manag Care 2006; 12:S111-S116.
2. Mannuel HD, Hussain A. What constitutes high-risk locally advanced prostate cancer? Clin Genitourin Cancer 2005; 4:193-196.
3. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005; 23:6992-6998.
4. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005; 224:1-22.
5. Clements JA,Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41:265-312.
6. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997; 57:4924-4930.
7. Jonsson M, Lundwall A, Linse S, Frohm B, Malm J. Truncated semenogelin I binds zinc and is cleaved by prostate-specific antigen. J Androl 2006; 27:542-547.
8. Denmeade SR, Isaacs JT. The role of prostate-specific antigen in the clinical evaluation of prostatic disease. BJU Int 2004; 93 (Suppl 1):10-15.
9. Gray MA. Clinical use of serum prostate-specific antigen: a review. Clin Lab 2005; 51:127-133.
10. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004; 101:894-904.
11. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194:755-763.
12. Savblom C, Malm J, Giwercman A, Nilsson JA, Berglund G, Lilja H. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 2005; 65:66-72.
13. Froehner M, Hakenberg OW, Koch R, Schmidt U, Meye A, Wirth MP, et al. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Urol Int 2006; 76:27-30.
14. Olsson AY, Bjartell A, Lilja H, Lundwall A. Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int J Cancer 2005; 113:290-297.
15. DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, et al. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 2002; 20:1874-1879.
16. Denmeade SR, Nagy A, Gao J, Lilja H, Schally AV, Isaacs JT. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Research 1998; 58:2537-2540.
17. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garret ES, Lilja H, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J NaH Cancer Inst 2003; 95:990-1000.
18. Williams SA, Merchant N, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. Design of a Prostate-specific antigen (PSA) activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007; 99: 376-385.
19. Buckley JT. The channel-forming toxin aerolysin. FEMS Microbiol Immunol 1992; 5:13-17.
20. Abrami L, Fivaz M, Glauser PE, Sugimoto N, Zurzolo C, van der Goot FG. Sensitivity of polarized epithelial cells to the pore-forming toxin aerolysin. Infect Immun 2003; 71:739-746.
21. Abrami L, Fivaz M, Decroly E, Seidah NG, Jean F, Thomas G, et al. The poreforming toxin proaerolysin is activatede by furin. J Biol Chem 1998; 273:32656-32661.
22. Lesieur C, Frutiger S, Hughes G, Kellner R, Pattus F, van der Goot FG. Increased stability upon heptamerization of the pore-forming toxin aerolysin. J Biol Chem 1999; 274:36722-36728.
23. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997; 57:4924-4930.
24. Wong KR, Green MJ, Buckley JT. Extracellular secretion of cloned aerolysin and phospholipase by Aermonas salmonicida. J Bacteriol 1989; 171:2523-2527.
25. Diep DB, Lawrence TS, Ausio J, Howard SP, Buckley JT. Secretion and properties of the large and small lobes of the channel-forming toxin aerolysin. Mol Microbiol 1998; 30:341-352.
26. Buckley JT. Purification of cloned proaerolysin released by a low protease mutant of Aeromonas salmonicida. Biochem Cell Biol 1990; 68:221-224.
27. Abi-Habib RJ, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts. Blood 2004; 104:2143-2148.
28. Liang Q, Chen L, Fulco AJ. An efficient and optimized PCR method with high fidelity for site-directed mutagenesis. PCR Methods Appl 1995; 4:269-274.
29. O'Connor KM, Fitzpatrick JM. Side-effects of treatments for locally advanced prostate cancer. BJU International 2005; 97:22-28.
30. Wong L, Suh DY, Frankel AE. Toxin conjugate therapy of cancer. Sem Oncol 2005; 32:591-595.
31. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001; 48:1-6.
32. Raben A, Chen H, Grebler A, Geltzeiler J, Geltzeiler M, Keselman I, et al. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up0 nomogram; improved target conformality with reduction in urethral and rectal wall dose. Int J Radiat Oncol Biol Phys 2004; 60:1631-1638.